BYLVAY Drug Patent Profile
When do Bylvay patents expire, and what generic alternatives are available?
Bylvay is a drug marketed by Ipsen and is included in one NDA. There are sixteen patents protecting this drug.
The generic ingredient in BYLVAY is odevixibat. One supplier is listed for this compound. Additional details are available on the odevixibat profile page.
DrugPatentWatch® Generic Entry Outlook for Bylvay
Bylvay was eligible for patent challenges on July 20, 2025.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 20, 2039. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for BYLVAY
BYLVAY is protected by twenty-eight US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of BYLVAY is ⤷ Start Trial.
This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BYLVAY
When does loss-of-exclusivity occur for BYLVAY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 19290337
Estimated Expiration: ⤷ Start Trial
Patent: 19290338
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2020024461
Estimated Expiration: ⤷ Start Trial
Patent: 2020024479
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 00687
Estimated Expiration: ⤷ Start Trial
Patent: 00691
Estimated Expiration: ⤷ Start Trial
Chile
Patent: 20003295
Estimated Expiration: ⤷ Start Trial
Patent: 20003296
Estimated Expiration: ⤷ Start Trial
China
Patent: 2262130
Estimated Expiration: ⤷ Start Trial
Patent: 2312893
Estimated Expiration: ⤷ Start Trial
Colombia
Patent: 20015772
Estimated Expiration: ⤷ Start Trial
Patent: 20015781
Estimated Expiration: ⤷ Start Trial
Costa Rica
Patent: 210026
Estimated Expiration: ⤷ Start Trial
Patent: 210027
Estimated Expiration: ⤷ Start Trial
Croatia
Patent: 0250427
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 10581
Estimated Expiration: ⤷ Start Trial
Ecuador
Patent: 21000999
Estimated Expiration: ⤷ Start Trial
Patent: 21001547
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 10084
Estimated Expiration: ⤷ Start Trial
Patent: 10581
Estimated Expiration: ⤷ Start Trial
Finland
Patent: 10581
Estimated Expiration: ⤷ Start Trial
Hungary
Patent: 70725
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 9464
Estimated Expiration: ⤷ Start Trial
Patent: 9468
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 48490
Estimated Expiration: ⤷ Start Trial
Patent: 04032
Estimated Expiration: ⤷ Start Trial
Patent: 21528415
Estimated Expiration: ⤷ Start Trial
Patent: 21528416
Estimated Expiration: ⤷ Start Trial
Jordan
Patent: 0200297
Estimated Expiration: ⤷ Start Trial
Patent: 0200299
Estimated Expiration: ⤷ Start Trial
Malaysia
Patent: 9425
Patent: CRYSTAL MODIFICATIONS OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Patent: 0563
Patent: PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 20013774
Estimated Expiration: ⤷ Start Trial
Patent: 20013839
Estimated Expiration: ⤷ Start Trial
New Zealand
Patent: 0458
Patent: Pharmaceutical formulation of odevixibat
Estimated Expiration: ⤷ Start Trial
Nicaragua
Patent: 2000103
Patent: MODIFICACIONES DE CRISTALES DE ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Patent: 2000104
Patent: FORMULACIÓN FARMACÉUTICA DE ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Peru
Patent: 210136
Patent: FORMULACION FARMACEUTICA DE ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Patent: 210182
Patent: MODIFICACIONES DE CRISTALES DE ODEXIBAT
Estimated Expiration: ⤷ Start Trial
Philippines
Patent: 020552165
Patent: PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Patent: 020552168
Patent: CRYSTAL MODIFICATIONS OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 10581
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 10581
Estimated Expiration: ⤷ Start Trial
Saudi Arabia
Patent: 0420731
Patent: صيغة صيدلانية لأوديفيكسيبات (Pharmaceutical Formulation of Odevixibat)
Estimated Expiration: ⤷ Start Trial
Serbia
Patent: 694
Patent: KRISTALNE MODIFIKACIJE ODEVIKSIBATA (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷ Start Trial
Singapore
Patent: 202012151X
Patent: CRYSTAL MODIFICATIONS OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Patent: 202012170P
Patent: PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Slovenia
Patent: 10581
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 2007541
Patent: CRYSTAL MODIFICATIONS OF ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 2811961
Estimated Expiration: ⤷ Start Trial
Patent: 210024032
Estimated Expiration: ⤷ Start Trial
Patent: 210024033
Estimated Expiration: ⤷ Start Trial
Patent: 260003419
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 11850
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 2012381
Patent: Crystal modifications of ODEVIXIBAT
Estimated Expiration: ⤷ Start Trial
Patent: 23954
Estimated Expiration: ⤷ Start Trial
Ukraine
Patent: 8761
Patent: КРИСТАЛІЧНІ МОДИФІКАЦІЇ ОДЕВІКСИБАТУ (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering BYLVAY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2011326871 | ⤷ Start Trial | |
| Brazil | 112013010157 | ⤷ Start Trial | |
| Canada | 2815749 | ⤷ Start Trial | |
| China | 103260625 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BYLVAY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3400944 | SPC/GB21/078 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ODEVIXIBAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING ODEVIXIBAT SESQUIHYDRATE; REGISTERED: UK EU/1/21/1566(NI) 20210719; UK PLGB 36216/0001 20210719; UK PLGB 36216/0002 20210719 |
| 3400944 | C202130067 | Spain | ⤷ Start Trial | PRODUCT NAME: ODEVIXIBAT; NATIONAL AUTHORISATION NUMBER: EU/1/21/1566; DATE OF AUTHORISATION: 20210716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1566; DATE OF FIRST AUTHORISATION IN EEA: 20210716 |
| 3400944 | 301157 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ODEVIXIBAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1566 20210719 |
| 3400944 | 2190043-6 | Sweden | ⤷ Start Trial | PRODUCT NAME: ODEVIXIBAT; REG. NO/DATE: EU/1/21/1556 20210719 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Summary
More… ↓
